Physician profile
Kenneth Eng
NPI 1134193865
$4,704.43
in general payments reported to CMS, 2019-2025
30 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $1,540 · 2021: $1,151 · 2022: $161 · 2023: $260 · 2024: $187 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $862.66 | 2019-2023 | Andexxa |
| Novo Nordisk INC | $759.34 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $336.23 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $319.85 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $304.84 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $303.22 | 2019-2021 | |
| Lilly USA, LLC | $281.78 | 2019-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $194.96 | 2020-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $194.09 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.06 | 2019-2021 | |
| Radius Health, INC. | $140.67 | 2019-2021 | |
| Intra-Sana Laboratories | $125.00 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Pfizer INC. | $110.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $87.17 | 2019-2021 | |
| Vifor Pharma, INC. | $85.02 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $78.63 | 2023 | |
| Amgen INC. | $68.72 | 2019-2022 | |
| Almatica Pharma LLC | $45.46 | 2025 | Teriparatide |
| Bayer Healthcare Pharmaceuticals INC. | $36.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.70 | 2019 | |
| Hikma Pharmaceuticals USA | $26.44 | 2021 | |
| Abbott Laboratories | $17.76 | 2025 | Proclaim |
| Dynavax Technologies Corporation | $17.38 | 2023 | Heplisav-B |
| La Jolla Pharmaceutical Company | $16.16 | 2024 | Giapreza |
| Shield Therapeutics INC | $14.35 | 2022 | |
| Esperion Therapeutics, INC. | $14.34 | 2020 | |
| Heron Therapeutics, INC. | $14.18 | 2025 | Aponvie |
| Eyevance Pharmaceuticals LLC | $13.91 | 2021 | |
| Sanofi Pasteur INC. | $13.49 | 2020 | |
| Ucb, INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Eng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.